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Henryk Marona 2 and Elżbieta Pękala 1
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Abstract: Effective protection from the harmful effects of UV radiation may be achieved by
using sunscreens containing organic or inorganic UV filters. The number of currently available
UV filters is limited and some of the allowed molecules possess limitations such as systemic
absorption, endocrine disruption properties, contact and photocontact allergy induction, and
low photostability. In the search for new organic UV filters we designed and synthesized a
series consisting of 5-benzylidene and 5-(3-phenylprop-2-en-1-ylidene)imidazolidine-2,4-dione
(hydantoin) derivatives. The photoprotective activity of the tested compounds was confirmed
in methanol solutions and macrogol formulations. The most promising compounds possessed
similar UV protection parameter values as selected commercially available UV filters. The compound
diethyl 2,2′-((Z)-4-((E)-3-(4-methoxyphenyl)allylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (4g)
was characterized as an especially efficient UVA photoprotective agent with a UVA PF of
6.83 ± 0.05 and favorable photostability. Diethyl 2,2′-((Z)-4-(4-methoxybenzylidene)-2,5-dioxo-
imidazolidine-1,3-diyl)diacetate (3b) was the most promising UVB-filter, with a SPFin vitro of 3.07± 0.04
and very good solubility and photostability. The main photodegradation products were geometric
isomers of the parent compounds. These compounds were also shown to be non-cytotoxic at
concentrations up to 50 µM when tested on three types of human skin cells and possess no estrogenic
activity, according to the results of a MCF-7 breast cancer model.
Keywords: UV-filters; UV radiation; 5-arylidenehydantoin derivatives; photoprotection; safety evaluation
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1. Introduction
Sunscreens are necessary to protect the skin against the acute and chronic consequences of
ultraviolet radiation (UVR). The main active ingredients of sunscreens called UV-filters are inorganic
blockers which reflect or scatter UVR or organic absorbers. Organic UV-filters act as chemical energy
converters—after absorption of photons the molecule is excited to a higher energy state, then the
absorbed energy is dissipated by the emission of photons or heat and molecule returns to the ground
state [1,2].
In the European Union sunscreen products are classified as cosmetics, but in the USA, Australia
and Canada they are recognized as over-the-counter (OTC) drugs, thus requirements for their safety
and efficacy are comparable with those of other dermatological drugs [3,4]. Modern organic UV-filter
molecules are expected to be not only UV-absorbers with high extinction coefficients, but they must
also be photostable, safe and readily soluble in cosmetics solvents. It is estimated that process
of commercialization of a new UV-filter takes about 10 years [5,6]. Typical exposure to UV-filters
is very high because of their concentration in sunscreens which reaches 10% for some organic
UV-filters. Moreover, the product is applied on the entire surface of the skin. Some UV-filters or
their metabolites were detected in the blood [7], urine [8,9] and milk of nursing mothers [10], what
indicates that these compounds penetrate into the bloodstream. More concerns appeared after several
adverse effects of currently used UV-filters were recognized. Many of them may cause endocrine
disruption [11–13] and adversely affect the viability of nerve cells, which may contribute to the
development of neurodegenerative diseases [14]. Additionally, benzophenone-3 showed cytogenetic
effect on human lymphocytes increasing micronuclei and chromosomal aberrations frequencies [15].
The other limitations of currently available UV-filters are related to contact and photocontact allergy
induction [16,17] and unsatisfactory photostability [18,19]. One of the most popular UVB-filter,
octinoxate (INCI: ethylhexyl methoxycinnamate, EHMC), upon ultraviolet irradiation undergoes
a photoisomerisation process, and the resulting Z-isomer has a lower extinction coefficient, which
results in a significant reduction in its photoprotectiveness [20]. Moreover, it was shown that the
photolysis products of EHMC are more toxic to the mammalian cells than EHMC alone. Low
photostablity also characterises an UVA-filter—avobenzone (INCI: butyl methoxy-dibenzoylmethane).
After irradiation its ability to absorb UVA is significantly reduced, additionally, it was shown that
arylglyoxals, the main products of avobenzone photodegradation, are strong sensitizers [21]. Due to
their unsatisfactory safety profile according to the European Commission regulations, in the latest
years two UV-filters—4-aminobenzoic acid (PABA) and 3-benzylidene camphor—have been banned
from use in cosmetics [22,23].
Considering the disadvantages of currently available UV-filters, the search
for new UV-filters remains an important issue. The list of UV filters allowed
in cosmetic products within the European Union is still expanding. In 2014
2,4,6-tris([1,1’-biphenyl]-4-yl)-1,3,5-triazine (INCI: trisbiphenyl triazine) was authorized [24],
whereas in 2018 2,2’-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) (INCI:
methylene bisbenzotriazolyltetramethylbutylphenol nano) was added to the list [25]. Moreover, several
scientific papers on this topic were published recently. Researchers have focused on modifications
of currently used compounds which represent derivatives of benzophenone, dibenzoylomethane,
benzotriazole, phenylbenzimidazole and cinnamic acid [26–30].
Derivatives of 5-arylideneimidazolidine-2,4-dione, depending of the presence and location of the
substituents on the phenyl or imidazolidine rings exhibit diverse biological activity. Their ability to
modulate cancer efflux pumps and the melanogenesis process, antimicrobial, and antiproliferative
activity, as well as α1-adrenoceptor antagonistic properties were reported [31–35]. Their ultraviolet
absorbing properties were also described [36,37], which prompted us to synthesize and evaluate the
photoprotective activity of a new series of 5-arylideneimidazolidine-2,4-dione (5-arylidenehydantoin)
derivatives. For further characterization of the most promising compounds we also performed tests
on their photostability and safety. We designed the compounds on the basis of the structure of
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3-benzylidenecamphor, in which the camphor fragment was replaced with a hydantoin moiety. We
anticipated that this structural change would positively affect the safety profile of the molecules
(Figure 1). We also planned several further modifications such as introduction of substituents in the
phenyl ring and/or hydantoin fragment as well as extension of the linker by adding an allyl group in
order to modify the physicochemical and photoprotective properties of the tested compounds.
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benzylidene moiety remained unchanged or was extended.
2. Results and Discussion
2.1. Chemistry
Synthesis and chemical structures of the tested compounds are shown in Scheme 1. These
compounds were obtained from appropriately substituted benzaldehyde (compounds 1a–1e, 2a–2e,
3a–3e, 5a) or cinnamaldehyde (compounds 4f–4h) and hydantoin.
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In the first step, appropriate 5-arylideneimidazolidine-2,4-diones (5-arylidenehydantoins,
compounds 1a–1h) were obtained by Knoevenagel condensations. Physicochemical analyses were
performed to confirm their structures and purity. Compounds 1a–1h served for further syntheses, while
compound 1e was also tested for its photoprotective properties and safety. Compounds 1a–1h were
used in reactions with ethyl chloroacetate or ethyl bromoacatate to synthesize substituted on nitrogen(s)
mono- (compounds 2a–2e) or diesters (compounds 3a–3e and 4f–4h), respectively. Additionally,
compound 2a was subjected to hydrolysis in order to obtain the corresponding acid (compound
5a). Chemical structures and purity of final compounds were confirmed by spectral analysis (NMR,
LC/MS/MS).
2.2. X-ray Crystallographic Studies
The molecular geometries in the crystal structures of 3b and 4g, together with the atom numbering
schemes, are shown in Figure 2.
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Figure 2. The molecular geometries of (a) 3b and (b) 4g, with the atom numbering schemes.
Displacement ellipsoids are drawn at the 30% probability level.
Both molecules contain a double bond between the C5 and C14 atoms. The crystal
structures confirm the Z arrangement at this bond. The molecule of 4g possesses an additional
double bond between the C15 and C16 atoms, and at this bond the E arrangement is observed.
The angles between the planes of the hydantoin and aromatic rings are 72.68(4)◦ and 9.21(7)◦
for 3b and 4g, respectively, which implies that the 5-benzylidenehydantoin fragment of 3b is
not planar, while the 5-cinnamylidenehydantoin fragment of 4g is almost planar. We have
previously determined crystal structures of 5-benzylidene-2-selenohydantoin derivatives, wherein the
5-benzylidene-2-selenohydantoin fragment is almost planar [38,39]. Considering that, we have carried
out a search in the Cambridge Structural Database (CSD) [40] for 5-benzylidenehydantoin (20 structures
found), 5-benzylidene-2-thiohydantoin (10 structures found) and 5-benzylidene-2-selenohydantoin
(two structures found) fragments. Most of the crystal structures deposited in the CSD possess
an almost planar benzylidene(thio/seleno)hydantoin moiety (Figure S1). The non-planarity of the
benzylidenehydantoin fragment is very seldom observed in crystal structures, while for thio- and
seleno-hydantoins it is not observed at all.
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The CSD includes no crystal structures containing cynnamylidenehydantoin moiety. We have
determined earlier the crystal structures containing similar fragment, namely cinnamylidene rhodanine
moiety [41], this fragment was also almost planar like in 4g.
Both investigated molecules possess the same 2-ethoxy-2-oxoethyl substituents at the nitrogen
atoms (N1 and N3). There are some differences in the mutual orientation of these substituents in
both molecules (Figure S2). The substituents at the N3 atom differ mainly in conformation of the
ethyl group. The C11-O6-C12-C13 torsion angle has values of −101.5(5)◦ (for occupancy A) in 3b and
88.0(2)◦ in 4g. Significant differences are visible in the conformation of the substituent at the N1 atom.
The torsion angle C5-N1-C6-C7 has values of −65.5(1)◦ and 67.8(2)◦ for 3b and 4g, respectively, what
implies opposite orientation of these substituents.
The crystal packing is determined by C-H···O intermolecular interactions (Table S1). In the 3b
two molecules, related by the inversion center, create dimers by C8-H8A···O4, C14-H14···O1 and
C16-H16···O1 intermolecular interactions (Figure 3a), while in 4g the are also observed dimers, but
created by other contacts, namely C14-H14···O4 and C16-H16···O4 (Figure 3b).
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methoxycinnamate or octocrylene. The presence of an additional N-alkyl substituent in the 
imidazolidine ring in compounds 3b–3e contributes to a hypsochromic shift by 15 nm (in compound 
3a by 21 nm) as well as a hypochromic effect (εmax decreased almost two-fold) when compared to N-
monosubstituted derivatives (compounds 2a–2e) which is consistent with former findings [42]. Thus 
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hydrogen bonds. The disordered fragment of 3b is depicted only for major occupancy.
2.3. Ultraviolet Spectroscopic Properties
Among tested compounds there are both UVA and UVB absorbers (λmax from 295 to 379 nm). Their
ultraviolet absorbing properties are presented in Table 1 and Figure S3. Compounds 2a–2e, which belong
to the group of ethyl esters of (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetic acid, absorb UV
radiation with different range, λmax and εmax depending on the presence and position of the auxochrome.
They show higher molar absorption coefficients and wider absorption ranges than commercially
used UV filters such as 4-methylbenzylidene camphor (4-MCB), ethylhexyl methoxycinnamate
or octocrylene. The presence of an additional N-alkyl substituent in the imidazolidine ring in
compounds 3b–3e contributes to a hypsochromic shift by 15 nm (in compound 3a by 21 nm) as well as a
hypochromic effect (εmax decreased almost two-fold) when compared to N-monosubstituted derivatives
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(compounds 2a–2e) which is consistent with former findings [42]. Thus N,N-bis-substituted derivatives
of 5-benzylideneimidazolidine-2,4-dione are slightly weaker UV absorbers than N-monosubstituted
derivatives, but their εmax still surpass octocrylene. The λmax of compounds 2a and 3a without
substituents on the phenyl ring is located in the UVB region (316 and 295 nm, respectively), while the
λmax of other 5-benzylideneimidazolidine-2,4-dione derivatives with methoxy groups is shifted to the
UVA II or UVA I region.
Table 1. Ultraviolet spectroscopic properties of the tested 5-arylideneimidazolidine-2,4-dione
derivatives and reference UV filters obtained in methanol solutions.
Compound Chemical Structure λmax [nm] εmax [M−1 cm−1] Absorption Range [nm]
1e
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Table 1. Ultraviolet spectroscopic properties of the tested 5-arylideneimidazolidine-2,4-dione 
derivatives and reference UV filters obtained in methanol solutions. 
Compound Chemical Structure 
λmax 
[n ] 
εm x [M−1 cm-
1] 
Absorption Range 
[nm] 
1e 
 
341 28440 290–384 
2a 
 
316 28460 290–345 
2b 
 
334 31920 290–372 
2c 
 
336 35610 290–376 
2d 
 
349 30700 290–394 
2e 
 
344 30740 290–381 
3a 
 
295 13980 290–335 
336 35610 290–376
2d
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2.4. Photoprotective Activity 
Absorption spectra and thus the photoprotective properties of UV-filters depend on the solvent 
used [43], hence to investigate the functional absorbing efficacy of the tested compounds and 
reference UV-filters (octocrylene, EHMC, 4-MBC, and avobenzone) they were tested in macrogol 
formulations (F1–F3) at 2% (w/w) concentration. 
The composition of formulations and concentration of tested compounds were based on their 
limited solubility. N-monosubstituted compounds 2a–2e were insoluble at desirable concentrations 
in the typical solvents used in cosmetic formulations such as alcohols, triacetin, surfactants, and co-
surfactants. To dissolve compounds 2a and 2b before incorporation to the formulation DMSO: Tween 
20 (1:9 w/w) was used, for less soluble 2c–2e it was necessary to use DMSO alone as solvent. 
Incorporation of an additional 2-ethoxy-2-oxoethyl substituent in the imidazolidine ring of N-mono-
substituted 5-arylidene-2,4-imidazolidinediones significantly improved the solubility of the 
compounds so it was possible to eliminate DMSO from the formulation and use the solvent system 
triacetin:Tween 20 (1 : 9 w/w) to dissolve compounds 3a–3e and 4f–4h before incorporation into the 
formulation. Thus the detailed composition of the formulations is as follows: F1–Tween 20 43.2%, 
PEG-400 25%, PEG-1500 25%, Triacetin 4.8%, tested compound 2%; F2–Tween 20 43.2%, PEG-400 
25%, PEG-1500 25%, DMSO 4.8%, tested compound 2%; F3–PEG-400 25%, PEG-1500 25%, DMSO 
48%, tested compound 2%. Considering the disadvantages of currently reported macrogol 
formulations and the low concentration achieved for the tested compounds (2%), we plan to work on 
cosmetic emulsions containing the most promising derivatives at higher concentrations as well as 
required excipients including preservatives, antioxidants, etc. This research will be carried out in the 
near future. 
The results of studies on the photoprotective activity of the tested compounds are presented in 
Table 2 and Figure 4. The performed study indicate that all tested compounds can be considered as 
potential UV-filters. In the group of ethyl esters of (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-
yl)acetic acid (compounds 2a–2e), compound 2a shows the highest value of SPFin vitro, which is 
comparable to EHMC SPFin vitro. This is related to the fact that the λmax of 2a is located in the UVB 
region. On the other hand, the λmax of compounds 2b–2e is shifted to UVA II (2b, 2c) or UVA I (2d, 
2e) region due to presence of electron donating groups in the phenyl ring, thus these compounds 
besides higher SPFin vitro than octocrylene, show higher efficiency in UVA absorption (UVA PF from 
4.29 ± 0.11 to 4.77 ± 0.24) than 2a and reference UV-filters excluding avobenzone. 
N,N-bis-substituted 5-benzylideneimidazolidine-2,4-dione derivatives 3a–3e may be 
characterized as slightly weaker UV-filters. Their SPFin vitro values range from 1.84 ± 0.02 to 3.07 ± 0.04. 
The highest values are found for compounds 3a (2.97 ± 0.45) and 3b (3.07 ± 0.04), which are lower 
than for EHMC and 4-MBC, but higher than for octocrylene. Additionally, compounds 3b–3e 
provides higher UVA protection in comparison to the reference UV-filters excluding avobenzone and 
range from 2.17 ± 0.11 for 3e to 2.59 ± 0.23 for 3b. 
Among (Z)-5-((E)-3-phenylallylidene)imidazolidine-2,4-dione derivatives 4f–4g there are strong 
potential UVA-filters. Their UVA PF values range from 4.28 ± 0.02 to 8.43 ± 1.35. The best efficacy is 
found for compounds 4f and 4g. The absorption curve of 4f is very similar to that of avobenzone, 
thus 4f seems to be a good candidate as a novel alternative to avobenzone in photoprotective 
formulations. Compound 4g shows lower UVA PF, despite higher molar absorption coefficient at its 
λmax when compared to 4f and avobenzone, which is probably caused by crystallization of the 
compound from solvents during formulation. The significantly higher UVA PF values of these 
compounds in comparison to 5-benzylideneimidazolidine-2,4-dione are associated with the presence 
of an additional conjugated double bond. The extension of the π-system contributes to the 
358 36820 290–393
The tested (Z)-5-((E)-3-phenylallylidene)imidazolidine-2,4-dione derivatives 4f–4h show the
highest m lar absorption coefficients among the tested series (especially compounds 4f and 4g).
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Elongation of the unsaturated spacer caused a significant bathochromic shift in comparison to the
corresponding benzylidene analogues. Their UV absorption ranges and λmax are very similar to those
of avobenzone, which is one of the most commonly used UV filters.
2.4. Photoprotective Activity
Absorption spectra and thus the photoprotective properties of UV-filters depend on the solvent
used [43], hence to investigate the functional absorbing efficacy of the tested compounds and reference
UV-filters (octocrylene, EHMC, 4-MBC, and avobenzone) they were tested in macrogol formulations
(F1–F3) at 2% (w/w) concentration.
The composition of formulations and concentration of tested compounds were based on their
limited solubility. N-monosubstituted compounds 2a–2e were insoluble at desirable concentrations
in the typical solvents used in cosmetic formulations such as alcohols, triacetin, surfactants, and
co-surfactants. To dissolve compounds 2a and 2b before incorporation to the formulation DMSO: Tween
20 (1:9 w/w) was used, for less soluble 2c–2e it was necessary to use DMSO alone as solvent. Incorporation
of an additional 2-ethoxy-2-oxoethyl substituent in the imidazolidine ring of N-mono-substituted
5-arylidene-2,4-imidazolidinediones significantly improved the solubility of the compounds so it
was possible to eliminate DMSO from the formulation and use the solvent system triacetin:Tween 20
(1:9 w/w) to dissolve compounds 3a–3e and 4f–4h before incorporation into the formulation. Thus the
detailed composition of the formulations is as follows: F1–Tween 20 43.2%, PEG-400 25%, PEG-1500
25%, Triacetin 4.8%, tested compound 2%; F2–Tween 20 43.2%, PEG-400 25%, PEG-1500 25%, DMSO
4.8%, tested compound 2%; F3–PEG-400 25%, PEG-1500 25%, DMSO 48%, tested compound 2%.
Considering the disadvantages of currently reported macrogol formulations and the low concentration
achieved for the tested compounds (2%), we plan to work on cosmetic emulsions containing the most
promising derivatives at higher concentrations as well as required excipients including preservatives,
antioxidants, etc. This research will be carried out in the near future.
The results of studies on the photoprotective activity of the tested compounds are
presented in Table 2 and Figure 4. The performed study indicate that all tested
compounds can be considered as potential UV-filters. In the group of ethyl esters of
(Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetic acid (compounds 2a–2e), compound 2a shows
the highest value of SPFin vitro, which is comparable to EHMC SPFin vitro. This is related to the fact
that the λmax of 2a is located in the UVB region. On the other hand, the λmax of compounds 2b–2e
is shifted to UVA II (2b, 2c) or UVA I (2d, 2e) region due to presence of electron donating groups
in the phenyl ring, thus these compounds besides higher SPFin vitro than octocrylene, show higher
efficiency in UVA absorption (UVA PF from 4.29 ± 0.11 to 4.77 ± 0.24) than 2a and reference UV-filters
excluding avobenzone.
N,N-bis-substituted 5-benzylideneimidazolidine-2,4-dione derivatives 3a–3e may be characterized
as slightly weaker UV-filters. Their SPFin vitro values range from 1.84 ± 0.02 to 3.07 ± 0.04. The highest
values are found for compounds 3a (2.97 ± 0.45) and 3b (3.07 ± 0.04), which are lower than for EHMC
and 4-MBC, but higher than for octocrylene. Additionally, compounds 3b–3e provides higher UVA
protection in comparison to the reference UV-filters excluding avobenzone and range from 2.17 ± 0.11
for 3e to 2.59 ± 0.23 for 3b.
Among (Z)-5-((E)-3-phenylallylidene)imidazolidine-2,4-dione derivatives 4f–4g there are strong
potential UVA-filters. Their UVA PF values range from 4.28 ± 0.02 to 8.43 ± 1.35. The best efficacy is
found for compounds 4f and 4g. The absorption curve of 4f is very similar to that of avobenzone, thus
4f seems to be a good candidate as a novel alternative to avobenzone in photoprotective formulations.
Compound 4g shows lower UVA PF, despite higher molar absorption coefficient at its λmax when
compared to 4f and avobenzone, which is probably caused by crystallization of the compound
from solvents during formulation. The significantly higher UVA PF values of these compounds in
comparison to 5-benzylideneimidazolidine-2,4-dione are associated with the presence of an additional
conjugated double bond. The extension of the π-system contributes to the bathochromic shift and
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higher extinction coefficient, thus UVA or broad spectrum UV-filters have higher molecular weight
than UVB filters [43].
Table 2. Photoprotective activity of tested compounds and reference UV-filters obtained in 2% (w/w)
macrogel formulations (F1*, F2#, F3ˆ).
Compound Chemical Structure SPFin vitro UVA PF λc UVA/UVB Ratio
2a#
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 Figure 4. UV absorption spectra of tested compounds and reference UV filters obtained in macrogol
formulation at 2% (w/w) concentration applied on polymethylmethacrylate plates. MPF–Monochromatic
Protection Factor.
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The impact of the presence and position of alkoxy groups in the phenyl ring is also visible when
another important parameters that characterize sunscreen formulations such as critical wavelength (λc)
and UVA/UVB ratio are compared. Compounds like 2a, 3a, 4f without substituents in the phenyl ring
show the lowest value of λc and UVA/UVB ratio in comparison to their analogues with alkoxy groups.
These values are increasing when substituents in the 4- (compounds 2b, 3b, 4g) and 3,4- (compounds
2e, 3e) positions are present and are the highest when electron donating groups are in the 2,4- position
(compounds 2d, 3d).
2.5. Photostability Studies
2.5.1. Photostability in Methanol Solutions
The photostability of the tested compounds in methanol solutions was investigated by
the measure of the changes in the λmax and in the area under curve (AUC) upon irradiation.
Results are presented in Table S2 and Figure S4. After irradiation of both mono- and diester
5-(Z)-benzylideneimidalidine-2,4-dione derivatives a bathochromic shift and slight hypochromic effect
are observed. In the group of monoesters with methoxy substituents on the phenyl ring (compounds
2b–2e) λmax shifts from 5 to 8 nm and decreases of the area under the curve from 0.96 to 4.33% are
found. In the case of compound 2a without a phenyl ring substituent, only a 1 nm shift of λmax and
almost a 30% decrease of AUC are found. After irradiation of diester derivatives 3a–3e, bathochromic
shifts from 6 to 11 nm are observed. The photostability of 3-phenylallylidene derivatives 4f–4h is
reduced in comparison to the benzylidene derivatives substituted on the phenyl ring (compounds
2b–2e, 3b–3e). Although no shifts are observed, the decrease of AUC reaches to 40.9% in the case
of the non-substituted derivative 4f. For compounds 4g and 4h with methoxy groups in the para or
ortho position, the decrease of AUC is 19.9 and 1.5%, respectively. In comparison to the reference
UV-filters, the tested compounds, excluding 4f, show better photostability than EHMC, for which a
36.7% decrease of AUC is detected.
The analysis of chromatograms and mass spectra of selected compounds obtained after appropriate
irradiation suggests that changes in absorption curves result from photoisomerisation processes taking
place in solution, which are a very efficient way of dispersing the absorbed energy that affects many
UV filters, e.g., cinnamic acid derivatives and benzylidene camphor derivatives [44] (Figure S5).
In post-irradiation chromatograms the additional peak with the same mass as tested compound
appears which indicates that the observed photoproduct is a geometric isomer. The percentage of
photoisomer formation range from 22.02 to 36.03%. In general, the tested compounds may be regarded
as photostable in methanol solutions.
2.5.2. Photostability in Cosmetic Formulations
After irradiation of thin layer of formulations applied on PMMA plates, their photoprotective
parameters were determined and compared with the pre-irradiation results. The study gives an
overview on functional photostability of the tested compounds. It is an important test, because
the photostability of some compounds in low concentrated solutions may meaningfully differ from
results obtained for higher concentrations used in sunscreen products [45]. According to the previous
studies, formulations whose SPF do not decrease more than 20% after irradiation are considered
photostable [46,47]. In the present study both UVB and UVA-absorbers were tested, so the changes in
SPFin vitro, UVA PF and AUC after irradiation are taken into account as a measure of photostability.
The tested were performed for formulations described in photoprotective activity section, the results
are presented in Table 3 and Figure 5.
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Table 3. The changes in photoprotective activity of tested compounds and reference UV-filters after
irradiation with solar light simulator at 500 W/m2. In the experiments appropriate formulations (F1*,
F2#, F3ˆ) were used.
Compound % of Initial SPFin vitro % of Initial UVA PF % of Initial AUC
2aˆ 33.25 37.87 46.72
2a# 55.49 68.96 62.42
2bˆ 36.51 24.13 35.28
2b# 57.19 54.31 59.55
2cˆ 44.37 35.83 34.13
2dˆ 75.69 51.45 58.87
2eˆ 56.00 38.99 41.99
3a* 83.31 103.50 88.19
3b* 80.46 87.04 84.67
3b* 72.69 84.08 76.50
3c* 88.73 86.59 85.29
3d* 89.92 97.66 94.01
3e* 81.28 87.10 79.59
4f* 62.24 25.98 27.92
4g* 86.29 34.39 51.98
4h* 82.22 62.38 69.19
4-MBC* 91.05 101.39 90.89
EHMC* 80.83 88.76 78.45
Results are presented as means from two independent experiments, at each determination six scans were performed.
*F1–Tween 20 43.2%, PEG-400 25%, PEG-1500 25%, Triacetin 4.8%, tested compound 2%; #F2–Tween 20 43.2%,
PEG-400 25%, PEG-1500 25%, DMSO 4.8%, tested compound 2%; ˆF3–PEG-400 25%, PEG-1500 25%, DMSO 48%,
tested compound 2%.
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Estrogenic activity of compounds was also determined, where the UV-filter benzophenone-2 (BP-2) 
exhibiting estrogenic activity was used as a positive control. Our preliminary safety assessment of 
the compounds also included evaluation of their metabolic stability. Skin not only is the major 
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Figure 5. UV absorption spectra of tested compounds and 4-MBC pre-irradiation and after 1 hour
irradiation with solar light simulator conducted at 500 W/m2 obtained in 2% (w/w) macrogol formulations.
Compounds 3a–3e in the macrogol formulation show the highest photostability–they may be
considered as photostable UV-absorbers. The decrease of SPFin vitro from 10.1 to 19.5% was observed.
The percentage of initial UVA PF and AUC values range from 103.5 to 87.0% and 94.0 to 79.6%
respectively. Especially compound 3d is characterized by functional photostability very similar to that
of 4-MBC which is considered a photostable UV-filter [48]. The analysis of chromatograms and mass
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spectra of selected compounds indicates that in macrogol formulations the compounds behave as in
methanol solutions. In the post-irradiation chromatogram of compound 3b, 32.1% of photoisomer
is observed while 28.4% is detected in methanol solution. Additionally, a new photoproduct with
2.4% relative peak area appears. Similarly, in the post-irradiation chromatogram of compound 3c,
a photoproduct with 2.8% relative peak area is detected. In the chromatogram of compound 3d no
additional peaks besides the photoisomer are found.
Interesting results are obtained for compounds 2a–2e. These compounds are insoluble in the
solvent system selected for compounds 3a–3e, thus it was necessary to dissolve them in DMSO before
incorporation into the formulation. The functional photostability of these compounds is drastically
reduced in comparison to the results obtained in methanol solutions. The decrease of tested parameters
is from 41.1% for 2d and reaches 75.9% for 2b. This was probably due to evaporation of the solvent
from the formulation and thus the precipitation of the compound. To confirm that the reason of the low
functional photostability of compounds 2a–2e was their precipitation, additional tests for compounds
2a and 2b in formulations containing a reduced amount of DMSO (from 48 to 4.8%) were carried out.
The results indicates an improvement of the functional photostability by 31.1% for 2a and by 30.2% for
2b. Additionally, the analysis of post-irradiation chromatograms of 2a shows that despite significant
changes in the reduction of photoprotection parameters between two formulations differing in the
content of DMSO, the percentage of photoisomer formation is very similar for both formulations (45%
vs 48%). These findings encourage us to search for another, better solvent system for compounds
2a–2e.
Photostability evaluation of compounds 4f–4h in macrogel formulations indicates that as in
methanol solutions they are not photostable. The decrease of their AUC was from 30.8% for 4h and
reached 72.1% for 4f. In the corresponding post-irradiation chromatograms, beside photoisomers, the
peaks of photodegradation products are also detected. The percentage of photoproducts content ranges
from 11.0% for 4h to 22.9% for 4f. This result does not discredit compounds 4f–4h. Low photostability
is also associated with other UV-filters, namely avobenzone and ethylhexyl methoxycinnamate, but it
can be improved by adding, for example, triplet-state quenchers to the formulations [20,49].
There are many factors that contribute to the photostability of a potential UV-filter molecule.
These compounds are from different chemical groups, their photobehaviour depends on the structure
and presence of functional groups. High photostability is a feature of molecules with intramolecular
hydrogen bonds such as hydroxyphenyltriazine derivatives. In this class of compounds after absorption
of a photon a tautomeric transfer of a H-atom to an N-atom is observed and then the absorbed energy
is lost as thermal energy (vibronic relaxation) [6]. Compounds containing unsaturated bonds (such as
derivatives of 5-arylidenehydantoin, camphor and cinnamic acid) after absorbing a photon undergo a
photoisomerisation process. This chemical transformation is a desirable way to lose absorbed energy.
It is most preferably when the cis and tans forms have similar absorption curve shapes and extinction
coefficients but forming a photoisomer often results in a significantly lower absorption intensity [20].
2.6. Preliminary Safety Assessment
The safety profile of selected compounds (1e, 2d, 2e, 3b, 4g, 4f and 5a) was evaluated. A
cytotoxicity assay in a unique skin panel model, containing three types of cells that are involved in the
structural organization of human skin was performed. Additionally, considering the possibility of
absorption of the compounds into the bloodstream and reports about adverse effects on viability of
nerve cells caused by some UV-filters [14], cytotoxicity against hepatocytes (HepG2) and neuroblastoma
cell lines (SH-SY5Y) was evaluated. As reference standards 4-MBC and/or BP-1 were used. A MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to investigate metabolic
activity of cells incubated in the presence of the analyzed compounds. Estrogenic activity of compounds
was also determined, where the UV-filter benzophenone-2 (BP-2) exhibiting estrogenic activity was used
as a positive control. Our preliminary safety assessment of the compounds also included evaluation of
their metabolic stability. Skin not only is the major protective environmental barrier, but also is involved
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in the biosynthesis of endogenous compounds, detoxification of xenobiotics and also participates in
the activation of pro-toxic substances [50]. As a consequence, metabolism studies are becoming a
consideration in the development of new cosmetic ingredients. The xenobiotic metabolising enzymes
within the epidermis in general represent the same classes as liver, although their levels are lower
and activities are weaker than those found in liver [51]. On the other hand xenobiotics such as some
cosmetic ingredients can enter into systemic circulation through the epidermis and dermis being
exposed to liver enzymes [52]. Therefore, we used rodents liver microsomes in this study to assess the
rate of stability of selected potential sunscreens. Additionally the mutagenic activity of two selected
compounds (3b, 4g) was examined.
2.6.1. Skin Panel Model
The cytotoxicity was examined after 24 h incubation of the cells with compounds. Results after
incubation at the higher administrated concentration are presented in Figure 6. Cytotoxicity studies
on human keratinocytes and human skin fibroblasts showed that all tested compounds except the
references 4-MBC and BP-1 are deprived of cytotoxic activity in the range of tested concentrations
(2–50 µM), and the viability of BJ cells and HaCaT is ≥87% and 89%, respectively (Figure 6a,b).
Cytotoxicity studies on human primary dermal melanocytes indicate a cell viability ≥68% at the highest
tested concentration except for BP-1 and 4-MCB, where the viability was <43% and 36% respectively
(Figure 6c).
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Figure 6. Viability of human keratinocytes HaCaT (a), human skin fibroblast (BJ) (b) cell lines, human
primary dermal melanocytes (c), HepG2 cells (d) and SH-SY5Y cells (e) incubated in the presence of
compounds at 50 µM for 24 hours. Cell viability was determined using MTT assay. Each experiment
was repeated in triplicate. Graphs represent the number of viable cells expressed as percent of control
(cells not treated with compounds) ± SEM (p < 0.05).
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2.6.2. Hepatocytotoxicity and Neurocytotoxicity Studies
Results after incubation of HepG2 cells and SH-SY5Y cells with the tested compounds and reference
compound 4-MBC at the highest (50 µM) concentration are presented in Figure 6. Cytotoxicity studies
on HepG2 hepatocellular tumor cells indicate that the tested 5-arylidene imidazolidine-2,4-dione
derivatives are safe at the concentrations used. In the MTT test, the viability of HepG2 cells at the
highest concentration is >75%. For reference compounds used in the test, the observed viability of cells
was <32%. Cytotoxicity studies on SH-SY5Y cells indicate the viability of cells >75% at the highest
tested concentration with exclusion of 4-MCB, where viability was <31% (Figure 6e).
2.6.3. Estrogenic Activity
Proliferation analyses indicated lack of stimulation effect of tested compounds in MCF-7 breast
cancer model. In contrast, BP-2 stimulated proliferation by over 60%, what was statistically significant.
Hence, lack of estrogenic activity of compounds was concluded. Results are presented in Figure 7.
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ND–not detected; NT–not tested. 
Figure 7. Proliferation rate of MCF-7 cells incubated with tested compounds at 5 µM. Compounds
showed lack of proliferation-stimulating effect. BP-2 increased MCF-7 proliferation by over 60%
(p < 0.05).
2.6.4. In Vitro Stability of Compounds in Mouse Liver Microsomes
Stability and direction of biotransformation of hydantoin derivatives in mouse liver
microsomes depend on the structure of the side chains. The metabolic stability
was evaluated by determining the half-life (t1/2) and intrinsic clearance (Clint) of the
compounds upon incubation (Table 4). In the group of studied structures the
most stable compound was 5a (((Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetic acid))
with t1/2 higher than 23 hours and the value of in vitro intrinsic clearance Clint
below 1 µL/mg/min. The least stable compound was proved to be 4g (diethyl
2,2′-((Z)-4-((E)-3-(4-methoxyphenyl)allylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate) with a
half-life of 3 min and value of Clint over 300 µL/mg/min. Other compounds’ stability remained
at a moderate level, most of them being slightly less stable than the reference BP-2.
We observed two directions of hydantoin derivatives’ microsomal biotransformation (Table 4).
One is O-dealkylation of compounds with alkoxy substituents on the phenyl ring (1e, 2c–e, 3b and 4g)
while the second is ester hydrolysis of diester derivatives 3b and 4g to monoesters.
Microsomal cytochrome P450 enzymes catalyze the oxidative O-dealkylation of xenobiotics,
cleaving methoxy or ethoxy groups in aromatic rings vulnerable to this reaction [53,54]. This reaction
requires the presence of NADPH. We observed O-de lkylation as a biotransformation reaction in case
of all tested structures bearing the methoxy (1e, 2d, 2e, 3b and 4g) or ethoxy (2c) side chains. Such
results are consistent with the previous reports regarding the biotransformation of structurally similar
compounds [53,55]. Apart from CYP450 isoforms other drug metabolizing enzymes are also present in
microsomal preparations including carboxylesterases [56] which mainly catalyze the hydrolysis of
diverse endogenous and xenobiotic esters. Carboxylesterases (CEs) are present in microsomal fractions
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of various tissues, including liver, intestine and skin [57]. CEs play crucial roles in the metabolism
of various ester xenobiotics including drugs [56] and cosmetic ingredients such as parabens [58,59],
or salicylates [60]. On the contrary to CYP450 enzymes no catalytic cofactors are involved in the
CEs-catalyzed reactions [59]. Therefore the interpretation of CEs contribution to microsomal stability
of compounds requires using additional blank incubations deprived not only NADPH regenerating
systems but also microsomes [59]. In our study all tested esters of hydantoin(di)acetic acid derivatives
(2c–2e, 3b, 4g) were stable in buffer at pH 7.4 in the absence of microsome solution showing no sign of
spontaneous hydrolysis after 60 min incubation at 37 ◦C (data not showed). Hydantoin derivative
1,3-diacetate diesters (3b and 4g) were hydrolysed to monoesters (parent compound losing 28 Da,
Table 4) in the presence of microsomes and independently of the presence of a NADPH-regenerating
system. The hydantoin 3-acetate monoesters derivatives 2c–2e did not hydrolyzed under the same
conditions. Therefore the most probable reaction is formation of 3-acetate monoesters from 3b and 4g
by mouse liver CEs. Formation of monoester from diester by mammalian liver microsomal CEs was
recently reported for di(2-ethylhexyl) phthalate [61].
Table 4. In vitro stability (t1/2 and Clint) of compounds 1e, 2c–2e, 3b, 4g, 5a and reference substance
benzophenone-2 (BP-2) in mouse liver microsomal system. Metabolites formation in the presence and
absence of NADPH; compounds elemental composition changes and probable transformation pathways.
Compound [M + H+] Da t 1
2
(min) Clint
(µL/mg/min)
Metabolite Formation in the
Presence (P) or/and Absence
(A) of NADPH
Elemental
Composition
Change
Probable
Transformation
1e 249 61 14 M1 P −14 O-dealkylation
2c 319 33 52 M1 a P −28 O-dealkylation
2d 335 15 59 M1a P −14 O-dealkylation
2e 335 41 21 M1 P −14 O-dealkylation
3b 391 12 75 M1 P and AM2 P
−28
−14
hydrolysis
O-dealkylation
4g 417 3 328 M1 P and AM2 P
−28
−14
hydrolysis
O-dealkylation
5a 247 1386 0.6 ND
BP-2 247 66 13 NT NT NT
ND–not detected; NT–not tested.
2.6.5. Mutagenic Activity
In the present study an Ames MPFTM Penta 2 microplate format mutagenicity assay (Xenometrix,
Allschwil, Switzerland) was used to evaluate mutagenicity of two selected compounds (3b and 4g)
exhibiting the most promising photoprotective potential. Growth, exposure and indicator media,
liver S9 fraction, S9-NADP, S9-G-6-P, positive control chemicals as well as Salmonella typhimurium and
Escherichia coli strains were included in the kit from Xenometrix. According to the obtained results,
there were no doses of test compounds 3b and 4g with more than a 2-fold induction over the baseline,
and a dose dependent response was not observed both in the absence and presence of metabolic
activation (Table S3). Therefore, compounds 3b and 4g were clearly non-mutagenic in the absence and
presence of metabolic activation.
2.7. Structure-Activity Relationship Studies
Monoethyl esters of (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetic acid (N-mono
substituted derivatives, compounds 2a–2e) absorbed UV radiation in methanol solutions in the
range of 290–394 nm with λmax 316–349 nm depending on the presence and position of the auxochrome.
An additional N-alkyl substituent in imidazolidine ring in compounds 3b–3e caused a hypsochromic
shift by 15–21 nm. Introduction of methoxy group(s) in the phenyl ring caused a shift of λmax from
the UVB region for compounds 2a and 3a to the UVA region for 2b–2e and 3b–3e. Elongation of the
unsaturated spacer between the phenyl and hydantoin rings in compounds 4f–4h contributed to the
significant bathochromic shift when compared to the appropriate benzylidene analogues leading to the
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extension of the UV absorption range into the UVA region. These compounds were also characterized
with the highest molar absorption coefficients among the tested series.
The tested compounds, especially 2a–2e, were difficult to dissolve in the proposed macrogol
formulations. In order to obtain a 2% formulation it was necessary to use DMSO because common
cosmetic solvents were not able to dissolve the compounds. However, we noticed that an additional
2-ethoxy-2-oxoethyl substituent in the imidazolidine ring (as in compounds 3a–3e) caused a significant
improvement of the solubility so that the use of DMSO in those formulations was not necessary.
Tests performed in formulations proved that compounds without methoxy substituents in the
phenyl ring were characterized as UVB filters while the presence of some methoxy groups shifted
the UV-protection properties into the UVA region which was observed as an increase of the UVA PF
value. Moreover, compounds without a substituent in the phenyl ring showed the lowest values of
critical wavelength (λc) and UVA/UVB ratio in comparison to their analogues possessing alkoxy groups.
Values of λc and UVA/UVB ratio increased with the following kind of substitution in the phenyl ring:
no substitution < 4-methoxy < 3,4-dimethoxy < 2,4-dimethoxy.
The currently reported compounds were shown to be less cytotoxic than commercially available
UV-filters at concentrations up to 50 µM in tested cell lines (human epidermal keratinocytes HaCaT,
human skin fibroblasts BJ, human primary epidermal melanocytes, human hepatoma cells HepG2,
human neuroblastoma cell line SH-SY5Y). The results suggest that exchange of camphor with hydantoin,
as presented in our design concept (Figure 1) caused an improvement of the safety profile.
3. Materials and Methods
3.1. Chemistry
2-Methoxycinnamalaldehyde, 4-methoxycinnamalaldehyde, ethyl chloroacetate and ethyl
bromoacetate were purchased from Sigma–Aldrich Chemie (Darmstadt, Germany), hydantoin
was obtained from TCI Chemicals (Tokyo, Japan), TEBA, 3,4-dimethoxybenzaldehyde and
cinnamalaldehyde were purchased from Alfa Aesar (Kandel, Germany), 4-ethoxybenzaldehyde
were purchased from Acros Organics (Geel, Belgium) whereas the reagents benzaldehyde,
4-methoxybenzaldehyde and 2,4-dimethoxybenzaldehyde were provided by Fluoro Chem (Hadfield,
England). Triacetin was obtained from ICN Biomedicals, Inc. (Irvine, CA, USA), PEG-400 and PEG-1500
were purchased from Merck (Darmstadt, Germany). Solvents were commercially available materials
of reagent grade. Melting points (mp) were uncorrected and were determined using a Buchi SMP-20
apparatus (Buchi Labortechnik, Flawil, Switzerland). The 1H-NMR (300 MHz) were obtained in CDCl3
with a Varian Mercury-VX 300 NMR spectrometer (Varian Inc., Palo Alto, CA, USA) using TMS as an
internal standard. Spectral data includes chemical shifts in ppm, multiplicities, constant couplings
in Hz, number of protons, protons’ positions. Multiplicities are abbreviated as follow: s (singlet), bs
(broad singlet), d (doublet), dd (doublet of doublets), ddd (double doublet of doublets), t (triplet), m
(multiplet). The LC/MS system consisted of an Acquity UPLC system (Waters Corporation, Milford,
MA, USA) coupled to a Waters TQD mass spectrometer (electrospray ionization mode ESI-tandem
quadrupole). All the LC/MS analyses were carried out using an Acquity UPLC BEH C18, 1.7µm,
2.1 × 100 mm column. A flow rate of 0.3 ml/min and a gradient of (5–95)% B over 10 min and then 100%
B over 2 min was used. Eluent A: water/0.1% HCO2H; eluent B: acetonitrile/0.1% HCOOH. LC/MS
data were obtained by scanning the first quadrupole in 0.5 s in a mass range from 50 to 1000 Da; 8
scans were added to produce the final spectrum.
3.1.1. Preparation of (Z)-5-benzylidene- and (Z)-5-((E)-3-phenylallylidene)imidazolidine-2,4-diones
(compounds 1a-1h)
Starting materials and compound 1e were synthesized by means of previously published
procedures [62]. Glacial acetic acid (100 mL) was mixed with anhydrous sodium acetate (33.3 g) in
round-bottom flask. Then hydantoin (10.1 g, 0.11 mole) was added and mixture was heated under
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reflux. After achieving boiling point, the appropriate aldehyde (0.1 mole) was added and the mixture
was heated for the next 4–8 h. After cooling the mixture was filtered and the obtained solid was washed
well with water. Dried crude product was crystallized from ethanol or ethanol/acetic acid (1:1).
3.1.2. Preparation of Ethyl (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetates (compounds
2a–2e)
The appropriate (Z)-5-beznylideneimidazolidine-2,4-dione (0.01 mole) was mixed with acetone
(100 mL) and potassium carbonate (4 g). Then TEBA (0.3 g, 0.001 mole) was added and the mixture was
heated under reflux with stirring. To the mixture ethyl chloroacetate (1.22 g, 0.01 M) in acetone (40 mL)
was added dropwise and the mixture was heated for 4 h. Then the reaction mixture was filtered, the
filtrate was evaporated under reduced pressure and the obtained crude product was recrystallized
from ethanol.
3.1.3. Preparation of Diethyl 2,2′-((Z)-4-benzylidene-2,5-dioxoimidazolidine-1,3-diyl) Diacetates and
Diethyl 2,2′-((Z)-2,4-dioxo-5-((E)-3-phenylallylidene)imidazolidine-1,3-diyl)diacetates (compounds
3a-3e, 4f-4h)
The appropriate (Z)-5-beznylideneimidazolidine-2,4-dione or (Z)-5-((E)-3-phenylallylidene)-
imidazolidine-2,4-dione (0.01 mole) was mixed with potassium carbonate (8 g), then DMF (30 mL) was
added. After dissolving the imidazolidine-2,4-dione derivative, ethyl bromoacetate (0.02 M, 3.34 g)
was added dropwise. The mixture was stirred at room temperature, while the progress of a reaction
was monitored by TLC (chloroform:acetone:methanol 5:1:0.1). After about 8 h the mixture was poured
into ice. Obtained solid was collected by filtration. After drying crude product was crystallized
from ethanol.
3.1.4. Preparation of (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetic acid (5a)
Ethyl (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetate (0.01 M) was mixed with ethanol
(50 mL) then NaOH (0.4 g, 0.01 M) dissolved in distilled water was added. The mixture was heated on
a water bath. After hydrolysis the solvent was distilled off. The obtained oily residue was dissolved in
distilled water then it was treated with 16% sulfuric acid with the aim of separating the free acid. The
crude product was crystallized from 50% ethanol.
3.1.5. Physicochemical Properties of Tested Compounds
(Z)-5-Benzylideneimidazolidine-2,4-dione (1a) was obtained as yellow solid (yield 74%), M = 188.19, mp
222–224 ◦C, ESI-MS (m/z): [M + H]+ calcd. for C10H8N2O2, 189.19, found, 189.01 100%. Physicochemical
data for 1a were previously published by Martínez-López et al. [63] CAS: 3775-01-7, CAS for Z
isomer: 74805-60-0.
(Z)-5-(4-Methoxybenzylidene)imidazolidine-2,4-dione (1b) was obtained as yellow solid (yield 72%),
M = 218.21, mp 251–252 ◦C, ESI-MS (m/z): [M + H]+ calcd. for C11H10N2O3, 219.21, found, 219.11
100%. Physicochemical data for 1b were previously published by Luo et al. [64] CAS: 5349-42-8, CAS
for Z isomer: 108402-52-4.
(Z)-5-(4-Ethoxybenzylidene)imidazolidine-2,4-dione (1c) was obtained as yellow solid (yield 81%),
M = 232.24, mp 229–231 ◦C, ESI-MS (m/z): [M+H]+ calcd. for C12H12N2O3, 233.24, found, 233.13
97.83%. Physicochemical data for 1c were previously published by Thenmozhiyal et al. [65] CAS:
6325-66-2, CAS for Z isomer: none.
(Z)-5-(2,4-Dimethoxybenzylidene)imidazolidine-2,4-dione (1d) was obtained as yellow solid (yield 82%),
M = 248.24, mp 238–240 ◦C, ESI-MS (m/z): [M + H]+ calcd. for C12H12N2O4, 249.24, found, 249.15 100%.
Physicochemical data for 1d were previously published by Thenmozhiyal et al. [65] CAS: 91559-39-6,
CAS for Z isomer: 1312438-16-6.
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(Z)-5-(3,4-Dimethoxybenzylidene)imidazolidine-2,4-dione (1e) was obtained as yellow solid (yield 69%),
M = 248.42, mp 279–280 ◦C, ESI-MS (m/z): [M + H]+ calcd. for C12H12N2O4, 249.42, found, 249.08
100%. Physicochemical data for 1e were previously published by Luo et al. [64] CAS: 10040-91-2, CAS
for Z isomer: 140894-76-4.
(Z)-5-((E)-3-Phenylallylidene)imidazolidine-2,4-dione (1f) was obtained as dark yellow solid (yield 73%),
M = 214.22, mp 272–274 ◦C, 1H-NMR (DMSO-d6) δ 11.09 (s, 1H, -NH-), 10.66 (s, 1H, -NH-), 7.54–7.44
(m, 2H, Ar-H3, Ar-H5), 7.44–7.20 (m, 4H, =CH-, Ar-H2, Ar-H4, Ar-H6), 6.86 (dd, J = 29.2, 15.7 Hz, 1H,
-CH=), 6.23 (dd, J = 11.9, 0.8 Hz, 1H, -CH=), ESI-MS (m/z): [M + H]+ calcd. for C12H10N2O2, 215.12,
found, 215.13 100%. Physicochemical data for 1f were previously published by Lamiri et al. [66] CAS:
66835-63-0, CAS for Z,E isomer: 137920-57-1.
(Z)-5-((E)-3-(4-Methoxyphenyl)allylidene)imidazolidine-2,4-dione (1g) was obtained as brown solid (yield
82%), M = 244.25, mp 289–291 ◦C, 1H-NMR (DMSO-d6) δ 11.02 (s, 1H, -NH-), 10.57 (s, 1H, -NH-), 7.43
(d, J = 8.7 Hz, 2H, Ar-H2, Ar-H6), 7.11 (dd, J = 15.5, 11.8 Hz, 1H, =CH-), 6.95 (d, J = 8.8 Hz, 2H, Ar-H3,
Ar-H5), 6.86 (d, J = 15.5 Hz, 1H, -CH=), 6.21 (dd, J = 11.8, 0.7 Hz, 1H, -CH=), 3.76 (s, 3H, O-CH3),
ESI-MS (m/z): [M + H]+ calcd. for C13H12N2O3, 245.25, found, 245.16 100%. CAS: 664353-78-0, CAS for
Z,E isomer: none.
(Z)-5-((E)-3-(2-Methoxyphenyl)allylidene)imidazolidine-2,4-dione (1h) was obtained as brown solid (yield
64%), M = 244.25, mp 260–263 ◦C, 1H-NMR (DMSO-d6) δ 11.05 (s, 1H, -NH-), 10.65 (s, 1H, -NH-), 7.55
(dd, J = 7.8, 1.7 Hz, 1H, Ar-H6), 7.33–7.16 (m, 2H, Ar-H4, -CH=C), 7.10 (d, J = 15.7 Hz, 1H, -CH=),
7.05–6.90 (m, 2H, Ar-H3, Ar-H5), 6.24 (d, J = 11.5 Hz, 1H, =CH-), 3.82 (s, 3H, -OCH3), ESI-MS (m/z): [M
+ H]+ calcd. for C13H12N2O3, 245.25, found, 245.10 98.85%. CAS for E,E isomer: 1776969-29-9, CAS for
Z,E isomer: none.
Ethyl (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetate (2a) was obtained as white solid (yield 63%)
M = 274.28, mp 169–171 ◦C, 1H-NMR (chloroform-d) δ 8.55 (s, 1H, -NH), 7.49–7.44 (m, 1H, Ar-H4),
7.44–7.30 (m, 4H, Ar-H2, Ar-H3, Ar-H5, Ar-H6), 6.79 (s, 1H, -CH=), 4.37 (s, 2H, -CH2-), 4.24 (q,
J = 7.2 Hz, 2H, -CH2-), 1.35–1.18 (m, 3H, -CH3), ESI-MS (m/z): [M + H]+ calcd. for C14H14N2O4, 275.28,
found, 275.20 96.84% CAS: 463317-70-6 CAS for Z isomer: 1416719-77-1.
Ethyl (Z)-2-(4-(4-methoxybenzylidene)-2,5-dioxoimidazolidin-1-yl)acetate (2b) was obtained as white solid
(yield 52%), M = 304.30, mp 178–179 ◦C, 1H-NMR (chloroform-d) δ 8.34 (s, 1H, -NH), 7.45–7.34 (m, 2H,
Ar-H2, Ar-H6), 7.01–6.90 (m, 2H, Ar-H3, Ar-H5), 6.76 (s, 1H, -CH=), 4.37 (s, 2H, N-CH2), 4.24 (q, J = 7.1
Hz, 2H, -CH2-), 3.85 (s, 3H, -OCH3), 1.29 (t, J = 7.1 Hz, 3H, -CH3) ESI-MS (m/z): [M + H]+ calcd. for
C15H16N2O5, 305.30, found, 305.17 99,31%. CAS: 463317-69-3 CAS for Z isomer: 2247638-41-9.
Ethyl (Z)-2-(4-(4-ethoxybenzylidene)-2,5-dioxoimidazolidin-1-yl)acetate (2c) was obtained as white solid
(yield 61%), M = 318.33, mp 181–182 ◦C, 1H-NMR (chloroform-d) δ 8.66–8.60 (m, 1H, -NH), 7.48–7.34
(m, 2H, Ar-H2, Ar-H6), 6.98–6.87 (m, 2H, Ar-H3, Ar-H5), 6.75 (s, 1H, -CH=), 4.37 (s, 2H, N-CH2), 4.23
(q, J = 7.2 Hz, 2H, -CH2-), 4.07 (q, J = 7.0 Hz, 2H, -CH2-), 1.43 (t, J = 7.0 Hz, 3H, -CH3), 1.36–1.19 (m, 3H,
-CH3) ESI-MS (m/z): [M + H]+ calcd. for C16H18N2O5, 319.33, found, 319.20 99.02%.
Ethyl (Z)-2-(4-(2,4-dimethoxybenzylidene)-2,5-dioxoimidazolidin-1-yl)acetate (2d) was obtained as light
yellow solid (yield 56%), M = 334.33, mp 197–198 ◦C, 1H-NMR (chloroform-d) δ 7.98 (s, 1H, -NH),
7.31–7.21 (m, 1H, Ar-H6), 6.75–6.68 (m, 1H, -CH=), 6.61–6.47 (m, 2H, Ar-H3, Ar-H5), 4.34 (s, 2H, -CH2-),
4.23 (q, J = 7.1 Hz, 2H, -CH2-), 3.93 (s, 3H, -OCH3), 3.85 (s, 3H, -OCH3), 1.34–1.21 (m, 3H, -CH3) ESI-MS
(m/z): [M + H]+ calcd. for C16H18N2O6, 335.33, found, 335.37 100%.
Ethyl (Z)-2-(4-(3,4-dimethoxybenzylidene)-2,5-dioxoimidazolidin-1-yl)acetate (2e) was obtained as white
solid (yield 48%), M = 334.33, mp 198–200 ◦C, 1H-NMR (chloroform-d) δ 8.41 (s, 1H, -NH), 7.10–7.00
(m, 1H, Ar-H6), 6.97–6.87 (m, 2H, Ar-H2, Ar-H5), 6.75 (s, 1H, -CH=), 4.36 (s, 2H, N-CH2), 4.23 (q,
J = 7.1 Hz, 2H, -CH2-), 3.93 (s, 3H, 3-OCH3), 3.92 (s, 3H, 4-OCH3), 1.28 (t, J = 7.2 Hz, 3H, -CH3), ESI-MS
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(m/z): [M + H]+ calcd. for C16H18N2O6, 335.33, found, 335.15 100%. CAS: 463317-68-2 CAS for Z
isomer: none.
Diethyl 2,2′-((Z)-4-benzylidene-2,5-dioxoimidazolidine-1,3-diyl)diacetate (3a) was obtained as white solid
(yield 81%), M = 360.37, mp 47–49 ◦C, 1H-NMR (chloroform-d) δ 7.39–7.30 (m, 3H, Ar-H3, Ar-H4,
Ar-H5), 7.26–7.19 (m, 2H, Ar-H2, Ar-H6), 7.01 (s, 1H, -CH2=), 4.37 (s, 2H, -CH2-), 4.23 (q, J = 7.2 Hz,
2H, -CH2-), 4.20 (s, 2H, -CH2-), 3.95 (q, J = 7.1 Hz, 2H, -CH2-), 1.28 (t, J = 7.2 Hz, 3H, -CH3), 1.09 (t,
J = 7.1 Hz, 3H, -CH3). ESI-MS (m/z): [M + H]+ calcd. for C18H20N2O6, 361.37, found, 361.27 96.74%.
Diethyl 2,2′-((Z)-4-(4-methoxybenzylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (3b) was obtained as
white solid (yield 79%), M = 390.39, mp 74–76 ◦C, 1H-NMR (chloroform-d) δ 7.24–7.13 (m, 2H, Ar-H2,
Ar-H6), 6.98 (s, 1H, -CH=), 6.95–6.84 (m, 2H, Ar-H3, Ar-H5), 4.38 (s, 2H, -CH2-), 4.30–4.18 (m, 4H,
-CH2-, -CH2-), 4.01 (q, J = 7.1 Hz, 2H, -CH2-), 3.83 (s, 3H, O-CH3), 1.30 (t, J = 7.2 Hz, 3H, -CH3), 1.12 (t,
J = 7.1 Hz, 3H, -CH3), ESI-MS (m/z): [M + H]+ calcd. for C19H22N2O7, 391.39, found, 391.17 100%.
Diethyl 2,2′-((Z)-4-(4-ethoxybenzylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (3c) was obtained as light
yellow solid (yield 84%), M = 404.42, mp 44–46 ◦C, 1H-NMR (chloroform-d) δ 7.22–7.11 (m, 2H, Ar-H2,
Ar-H6), 6.97 (s, 1H, -CH=), 6.95–6.82 (m, 2H, Ar-H3, Ar-H5), 4.37 (s, 2H, N1-CH2), 4.30–4.15 (m, 4H,
N3-CH2, -CH2-), 4.02 (dq, J = 12.6, 7.1 Hz, 4H, -CH2-, -CH2-), 1.42 (t, J = 7.0 Hz, 3H, -CH3), 1.34–1.21
(m, 3H, -CH3), 1.17–1.04 (m, 3H, -CH3), ESI-MS (m/z): [M + H]+ calcd. for C20H24N2O7, 405.42, found,
405.26 100%.
Diethyl 2,2′-((Z)-4-(2,4-dimethoxybenzylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (3d) was obtained
as white solid (yield 75%), M = 420.42, mp 88–90 ◦C, 1H-NMR (chloroform-d) δ 7.05 (dt, J = 8.1, 0.7 Hz,
1H, Ar-H6), 6.94 (s, 1H, -CH=), 6.54–6.41 (m, 2H, Ar-H3, Ar-H5), 4.36 (s, 2H, -CH2-), 4.29–4.16 (m, 4H,
-CH2-, -CH2-), 4.00 (qd, J = 7.1, 0.6 Hz, 2H, -CH2-), 3.82 (s, 3H, 4-OCH3), 3.79 (s, 3H, 2-OCH3), 1.34–1.21
(m, 3H, -CH3), 1.12 (t, J = 7.1, 0.6 Hz, 3H, -CH3), ESI-MS (m/z): [M + H]+ calcd. for C20H24N2O8, 421.42,
found, 421.22 100%.
Diethyl 2,2′-((Z)-4-(3,4-dimethoxybenzylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (3e) was obtained as
light yellow solid (yield 68%), M = 420.42, mp 80–82 ◦C, 1H-NMR (chloroform-d) δ 6.97 (s, 1H, -CH=),
6.90–6.78 (m, 2H, Ar-H5, Ar-H6), 6.76 (d, J = 1.8 Hz, 1H, Ar-H2), 4.38 (s, 2H, -CH2-), 4.32–4.16 (m, 4H,
-CH2-,-CH2-), 4.01 (qd, J = 7.2, 0.6 Hz, 2H, -CH2-), 3.90 (s, 3H, -OCH3), 3.86 (s, 3H, -OCH3), 1.33–1.25
(m, 3H, -CH3), 1.18–1.05 (m, 3H, -CH3). ESI-MS (m/z): [M + H]+ calcd. for C20H24N2O8, 421.42, found,
421.22 100%.
Diethyl 2,2′-((Z)-2,4-dioxo-5-((E)-3-phenylallylidene)imidazolidyne-1,3-diyl)diacetate (4f) was obtained as
yellow solid (yield 84%), M = 386.40, mp 99–100 ◦C, 1H-NMR (DMSO-d6) δ 7.57–7.49 (m, 2H, Ar-H2,
Ar-H6), 7.49–7.25 (m, 3H, Ar-H3, Ar-H4, Ar-H5), 7.18–7.00 (m, 2H, -CH=, -CH-), 6.66–6.53 (m, 1H,
=CH-), 4.92 (s, 2H, -CH2-), 4.35 (d, J = 4.1 Hz, 2H, -CH2-), 4.22–4.06 (m, 4H, -CH2-, -CH2-), 1.26–0.98
(m, 6H, -CH3, -CH3), ESI-MS (m/z): [M + H]+ calcd. for C20H22N2O6, 387.40, found, 387.19 100%.
Diethyl 2,2′-((Z)-4-((E)-3-(4-methoxyphenyl)allylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (4g) was
obtained as yellow solid (yield 89%), M = 416.43, mp 134–135 ◦C, 1H-NMR (DMSO-d6) δ 7.55–7.42 (m,
2H, Ar-H2, Ar-H6), 7.12–6.86 (m, 4H, -CH=, =CH-, Ar-H3, Ar-H5), 6.55 (d, J = 11.9 Hz, 1H, -CH=), 4.90
(s, 2H, -CH2-), 4.35 (s, 2H, -CH2-), 4.13 (qd, J = 7.1, 3.7 Hz, 4H, -CH2-, -CH2-), 3.77 (s, 3H, O-CH3), 1.19
(t, J = 7.1 Hz, 3H, -CH3), 1.13 (t, J = 7.1 Hz, 3H, -CH3). ESI-MS (m/z): [M + H]+ calcd. for C21H24N2O7,
417.43, found,417.16 100%.
Diethyl 2,2′-((Z)-4-((E)-3-(2-methoxyphenyl)allylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate (4h) was
obtained as yellow solid (yield 75%), M = 416.43, mp 134–135 ◦C, 1H-NMR (chloroform-d) δ 7.38 (dd,
J = 7.7, 1.7 Hz, 1H, Ar-H6), 7.36–7.18 (m, 2H, -CH=, -CH=), 7.17–7.03 (m, 1H, Ar-H4), 7.00–6.75 (m, 2H,
=CH-, Ar-H5), 6.69 (dd, J = 11.0, 0.6 Hz, 1H, Ar-H3), 4.72 (s, 2H, -CH2-), 4.36 (s, 2H, -CH2-), 4.24 (qd,
J = 7.2, 6.1 Hz, 4H, -CH2-, -CH2-), 3.89 (s, 3H, 2-OCH3), 1.36–1.11 (m, 6H, -CH3, -CH3), ESI-MS (m/z):
[M + H]+ calcd. for C21H24N2O7, 417.43, found, 417.29 97.93%.
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(Z)-2-(4-Benzylidene-2,5-dioxoimidazolidin-1-yl)acetic acid (5a) was obtained as white solid (yield 49%),
M = 246.22, mp 215–217 ◦C, 1H-NMR (DMSO-d6) δ 10.91 (s, 1H, -OH), 7.69–7.59 (m, 2H, -NH, Ar-H4),
7.47–7.28 (m, 4H, Ar-H1, Ar-H2, Ar-H5, Ar-H6), 6.58 (s, 1H, -CH=), 4.19 (s, 2H, -CH2-)., ESI-MS
(m/z): [M + H]+ calcd. for C12H10N2O4, 247.22, found, 247.16 100%. CAS: 857796-52-2 CAS for Z
isomer: 850636-92-9.
3.2. Crystal Structures of 3b and 4g
Crystals suitable for an X-ray structure analysis were obtained from ethanol by slow evaporation
of the solvent at room temperature. Data for single crystals were collected using the Oxford Diffraction
SuperNova four circle diffractometer (Agilent, Wroclaw, Poland), equipped with the Mo (0.71073 Å)
Kα radiation source and graphite monochromator. The phase problems were solved by direct methods
using SIR-2014 program [67]. All non-hydrogen atoms were refined anisotropically using weighted
full-matrix least-squares on F2. Refinement and further calculations were carried out using SHELXL
program [68]. The hydrogen atoms bonded to carbons were included in the structure at idealized
positions and were refined using a riding model with Uiso(H) fixed at 1.2 Ueq of C and 1.5 Ueq for
methyl groups. The fragment O6-C12-C13 in 3b is disordered. The occupancy factors of these atoms
after refinement are 0.797 and 0.203 for the major (A) and minor (B) components, respectively. For
molecular graphics ORTEP [69] and MERCURY [70] programs were used.
3b: C19H22N2O7, Mr = 390.38, crystal size = 0.21 × 0.44 × 0.77 mm3, monoclinic, space group C2/c,
a = 22.7269(5) Å, b = 12.7839(2) Å, c = 13.7085(6) Å, β = 106.579(2)◦, V = 3817.3(1) Å3, Z = 8, T = 130(2) K,
14040 reflections collected, 4450 unique reflections (Rint = 0.0163), R1 = 0.0360, wR2 = 0.0887 [I > 2σ(I)]
and R1 = 0.0417, wR2 = 0.0929 [all data].
4g: C21H24N2O7, Mr = 416.42, crystal size = 0.17 x 0.23 x 0.79 mm3, monoclinic, space group I2/a,
a = 17.7480(2) Å, b = 8.8899(1) Å, c = 27.1816(3) Å, β = 96.619(1)◦, V = 4116.31(8) Å3, Z = 8, T = 130(2)
K, 27541 reflections collected, 4942 unique reflections (Rint = 0.0202), R1 = 0.0435, wR2 = 0.1031 [I >
2σ(I)] and R1 = 0.0526, wR2 = 0.1094 [all data].
CCDC 1889259-1889260 contain the supplementary crystallographic data. These data can be
obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/
data_request/cif.
3.3. Ultraviolet Spectroscopy
Spectra with a scan range of 290–400 nm were recorded in 50 or 25 µM methanol solutions, in
1 cm path length, 1.5 mL quartz cuvettes on a U-2800 double beam spectrophotometer (Hitachi, Tokyo,
Japan) controlled by UV Solution version 2.2 software. The molar extinction coefficient at maximum
absorption (εmax) of tested compounds was determined in methanol as the slope of the linear regression
of absorbance vs. concentration of tested compound (from 10 to 50 µM or 2.5 to 30 µM).
3.4. Photoprotective Activity
3.4.1. Cosmetic Formulations
Tested compounds and commercial UV filters as reference standards were incorporated to a
neutral macrogel formulation in the concentration of 2%. Prior to the incorporation, compounds 3a–3e
and 4f–4h and reference UV-filters were dissolved in a triacetin:Tween 20 (1:9) solvent system. For
compounds 2a–2e it was necessary to use DMSO. The final composition of the macrogol formulations
is presented in the photoprotective activity section.
3.4.2. In Vitro Photoprotection Study
In vitro photoprotection study was performed according to EN ISO 24443:2012 [71] with slight
modifications. Formulation with tested compound (32.5 mg) was applied on a polymethylmethacrylate
plate (PMMA) with the application area 25 cm2 and 5 µm roughness value to simulate the skin surface
Molecules 2019, 24, 2321 22 of 29
(Schonberg GmbH, Hamburg, Germany). As a reference a PMMA plate treated with approximately
15 µL of glycerin was used. Measurements were carried out by reflectance spectrophotometry with
SPF-290AS Analyser (Solar Light Company, Glenside, PA, USA) equipped with integrating sphere
controlled by WinSPF version X.X. software. For each sample two plates were prepared, absorbance
measures were performed on 6 different positions of the plate from 290 to 400 nm with 1 nm steps. The
results were expressed as an average of data from 12 scans.
3.4.3. Photostability Study
The photostability evaluation of compounds was performed both in methanol solutions and in
macrogol formulations. Irradiation of samples according to previous studies [29,72] was conducted
for 1 h at 500 W/m2 (cumulative dose of ultraviolet radiation 218 kJ/m2) with solar light simulator
(Suntest CPS+, Atlas, Linsengericht, Germany) equipped with an optical filter cutting off wavelengths
shorter than 290 nm and IR-block filter to neutralize thermal effects. The UV absorption spectrum of
the samples were analysed post-irradiation and compared with pre-irradiation results. UPLC-MS/MS
analyses were also performed.
Methanol solutions were tested at concentration 25 or 50 µM in quartz cuvettes with the PTFE
stopper to prevent evaporation or leaking of the solvent. Macrogol formulations (2% w/w) were
tested on PMMA plates (1.3 mg/cm2). After post-irradiation measure of UV absorption, exposed and
unexposed plates were washed with 5 mL of methanol, then mixtures were filtered and analysed by
UPLC-MS/MS. All analyses were performed in duplicates.
3.5. Skin Panel Model
Primary Epidermal Melanocytes (PCS-200-013, ATCC; Manassas, VA, USA), human epidermal
keratinocyte cell line HaCaT (CLS Cell Lines Service; Eppelheim, Germany) and human skin fibroblast
cell line BJ (CRL-2522, ATCC,) were used in the study. Primary Epidermal Melanocytes were cultured
in Dermal Cell Basal Medium (ATCC) supplemented with Adult Melanocyte Growth Kit Components
(ATCC), HaCaT and BJ cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; New
York, NY, USA) and supplemented with 10% fetal bovine serum (FBS; Gibco, New York, NY, USA).
Cell maintenance was performed in a humidified incubator at 37 ◦C with 5% CO2. Cells were passage
when the culture has reached approximately 80 to 90% confluence. Cells were seeded at density of
6 × 103 on 96-well plates. Following overnight culture, the cells were then treated with increasing
doses of compounds and incubated for 24 h. Following cell exposure to each drug for 24 h, 10 µL
MTT reagent (Sigma Aldrich, Darmstadt, Germany) was added to each well. After 4 hours incubation
(37 ◦C, 5% CO2), the medium was aspirated and the formazan produced in the cells appeared as dark
crystals in the bottom of the wells. Next, DMSO (dissolving solution) was added to each wells. Then
the optical density (OD) of solution was determined at 570 nm on micro plate reader (Spectra iD3 Max,
Molecular Devices; San Jose, CA, USA). Viability (% of control) was determined by dividing A570 of
experimental wells by of A570 of control wells × 100%.
3.6. Hepatocytotoxicity and Neurocytotoxicity Studies
For hepatotoxicity and neurotoxicity assays a human neuroblastoma cell line—SH-SY5Y
(CRL-2266™, ATCC) and a human hepatocellular carcinoma cell line–HepG2, respectively have
been used. Cells were seeded on 96-well plates at an initial density of 10,000 cells per well. Cells were
cultured in standard conditions for 24 h and then study compounds were administrated at different
concentrations (10–50 µM) for another 24 h. After incubation time cells viability was measured with
MTT assay. For this purpose culture medium has been replaced for the fresh one and MTT reagent
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) has been added at the concentration
0.5 mg/mL. Cells were incubated with MTT reagent at 37 ◦C for 4 h. Then formazan crystals have been
dissolved in DMSO solution and the absorbance has been measured at 570 nm. Experiments were
conducted in triplicates. Values represent mean percent of viability (in the percent of control).
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3.7. Estrogenic Activity
To determine estrogenic activity of tested compounds their influence on estrogen-dependent
MCF-7 breast cancer cell line proliferation was investigated. Cells were seeded into 24-wells plates
in density of 40,000 per well. After 24 h incubation, cells were washed twice with PBS and fresh,
estrogen- and phenol red-free medium (DMEM low-glucose; 2,5% Charcoal Stripped FBS; 2 mM
glutamine; Sigma Aldrich, Darmstadt, Germany) was added. Than cells were incubated with tested
compounds or benzophenone-2 (BP-2; Sigma Aldrich, Darmstadt, Germany), which is a UV filter
exhibiting estrogenic activity, to final concentration of 5 µM. After 120 h incubations, cells proliferation
was determined with crystal violet assay. Briefly, cells were washed with PBS and fixed with 3,7%
formaldehyde. Then, crystal violet solution was added for 10 minutes. After incubation, solution
was removed and cells were washed five times with PBS. Crystal violate was extracted from cells
using destaining solution (1,33% citric acid, 1,09% sodium citrate in water/methanol (1:1) solution) and
absorbance of the solution was determined at 570 nm (A570). Proliferation rate was determined by
dividing the A570 of experimental wells by the A570 of control wells × 100%.
3.8. In Vitro Stability of Compounds in Mouse Liver Microsomes
Mouse liver microsomes (MLMs) were used to investigate the phase I metabolism of selected
compounds (2c, 2d, 3b, 4g, 5a) and the reference substance BP-2. Samples composed of test compound
(20 µM), MLMs (0.8 mg/mL) and potassium phosphate buffer (100 mM, pH 7.4) were preincubated
prior to addition of NADPH-regenerating system. NADPH-regenerating system contained NADP,
glucose-6-phosphate, glucose-6-phosphate dehydrogenase and potassium phosphate buffer (100 mM,
pH 7.4). Control incubations were performed in the absence of the NADPH-regenerating system [73]
and in case of esters (2c, 2d, 3b and 4g) without the mouse liver microsomes solution to determine
spontaneous hydrolysis [59]. Incubations were conducted at 37 ◦C for at least 15 min up to 60 min.
The reactions were stopped by the addition of 250 µL ice-cold methanol containing internal standard
PTX (20 µM). The mixture was then centrifuged. Supernatant analysis was performed using UPLC/MS
(Waters Corporation). The assays were repeated two times. The in vitro half times (t1/2) for test
compounds were determined from the slope of the linear regression of ln % parent compound
remaining versus incubation time. The calculated t1/2 was incorporated into the following equation to
obtain intrinsic clearance: (Clint) = (volume of incubation [µL]/ protein in the incubation [mg]) × 0.693 /
t1/2 [74].
3.9. Ames Assay
The assay is a liquid microplate modification of the traditional Salmonella test [75,76]. During
the procedure, bacteria are exposed to different concentrations of a test compound for 90 min in a
medium containing sufficient histidine (S. typhimurium) or tryptophan (E. coli) to support cell divisions.
Then, the cultures are diluted in pH indicator medium lacking histidine or tryptophan and aliquoted
into 48 wells of a 384-well plate. Within 48 hours, cells that have undergone reversion to amino acid
prototrophy will grow into colonies. Bacterial metabolism reduces pH of the medium, changing the
color of that well from purple to yellow (https://www.xenometrix.ch [77]).
The following strains were used in the study: S. typhimurium TA98, TA100, TA1535, TA1537
and E. coli wp2 uvrA[pKM101]. TA100, TA1535 and E. coli strains are used for the detection of base
substitution mutations, whereas TA98 and TA1537 are utilized for the detection of frameshift mutations.
S. typhimurium strains have GC base pairs, whereas E. coli strain has AT base pair at their primary
reversion site and detect certain oxidizing mutagens, cross-linking agents and hydrazines.
The test procedure provided by Xenometrix (https://www.xenometrix.ch [77]) and described
earlier was followed [78–80]. Briefly, the bacterial strains were grown overnight in exposure medium
and exposed to test compounds 4g and 3b in 24-well plates for 90 min at 37 ◦C with agitation in
the absence (–S9) or presence (+S9) of 4.5% phenobarbital/ β-naphthoflavone-induced rat liver S9.
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Compounds 4g and 3b were dissolved in DMSO and tested at final concentrations of 0.1, 0.2 and
0.5 mM. After the preincubation, the cultures were diluted in the indicator medium and the contents of
each 24-well culture were distributed into 48 wells on a 384-well plate and incubated further for 48 h at
37 ◦C without agitation. After the exposure, the number of wells containing bacteria was scored by eye
for yellow wells. Positive and negative controls were included in the assay, and all doses were done
in triplicate.
Positive controls used for the MPF protocol were 2-nitrofluorene (2-NF) at 2 µg/mL (TA98,
–S9); 4-nitroquinoline-N-oxide (4-NQO) at 0.1 µg/mL (TA100, –S9); N4-aminocytidine (N4-ACT) at
100 µg/mL (TA1535, –S9); 9-aminoacridine (9-AAc) at 15 µg/mL (TA1537, -S9); 4-NQO at 2 µg/mL
(E.coli uvrA[pKM101], –S9); 2-aminoanthracene (2-AA) at 0.5 µg/mL (TA98, + S9); 2-AA at 1.25 µg/mL
(TA100, + S9); 9-AA at 2.5 µg/mL (TA1535 and TA1537, + S9); 2-aminofluorene (2-AF) at 400 µg/mL
(E.coli uvrA[pKM101], + S9). Pure DMSO was used as the negative control.
To evaluate the test results the following criteria were used: the fold increase in the number of
positive wells over the solvent control baseline (FIB), and the dose dependency. The fold increase of
revertants relative to the solvent control was determined by dividing the mean number of positive
wells at each dose by the solvent control at baseline. The solvent control at baseline was defined as
the mean number of positive wells in the solvent control plus one standard deviation (SD). When an
increase of more than 2-fold relative to the baseline at more than one dose with a dose–response is
observed the sample is classified as positive, whereas when no response >2 times the baseline and no
dose–response is stated the sample is negative [76–80].
4. Conclusions
In summary all tested compounds may be considered as potential UVA or
UVB filters. Their absorption parameters are comparable or more favorable
than those of selected commercially available UV-filters. Compound 4f (diethyl
2,2′-((Z)-2,4-dioxo-5-((E)-3-phenylallylidene)-imidazolidyne-1,3-diyl)diacetate) shows the best UVA
photoprotective properties among the tested series with a UVA PF of 8.43 ± 1.35 but its photostability
is unsatisfactory. Compound 2a (ethyl (Z)-2-(4-benzylidene-2,5-dioxoimidazolidin-1-yl)acetate)
shows the best UVB photoprotective properties within the tested series with a SPFin vitro
of 4.79 ± 0.02, but it is only slightly soluble in the formulations used. Considering
the other features of modern UV-filters such as good solubility in cosmetic solvents and
high photostability, the most favorable UVA-filter seems to be compound 4g (diethyl
2,2′-((Z)-4-((E)-3-(4-methoxyphenyl)allylidene)-2,5-dioxoimidazolidine-1,3-diyl)diacetate) with a UVA
PF of 6.83 ± 0.05 and better photostability than compound 4f. The most promising potential UVB-filter
is compound 3b (diethyl 2,2′-((Z)-4-(4-methoxybenzylidene)-2,5-dioxoimidazolidine-1,3-diyl)-
diacetate) with SPFin vitro of 3.07 ± 0.04, characterized by very good solubility and photostability.
The preliminary safety assessment of the compounds is also promising. Tested compounds at high
concentrations (50 µM) are non-toxic toward human skin cells, hepatoma and neuroblastoma cells and
possess no estrogenic activity. We may conclude that neither test compounds 3b and 4g nor their
potential metabolites are base substitution or frameshift mutagens. Their metabolic stability is various
and depends on substituents in phenyl and imidazolidine ring.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/12/2321/
s1, Figure S1: The distribution of the angle values between the planes of hydantoin and aromatic rings
in crystal structures containing a 5-benzylidenehydantoin (hyd), 5-benzylidene-2-thiohydantoin (S-hyd) or
5-benzylidene-2-selenohydantoin (Se-hyd) fragment retrieved from the CSD. Figure S2: The overlap of hydantoin
rings of 3b (carbon atoms in grey) and 4g (carbon atoms in green). The disordered fragment of 3b is depicted only
for major occupancy (A). Figure S3: UV-absorption spectra of tested compounds and reference UV filters obtained
in methanol solutions (for 2a–2e, 3a–3e, octocrylene and EHMC at 50 µM, for 4f–4h and avobenzone at 25 µM).
Figure S4: UV absorption spectra of tested compounds and EHMC obtained pre-irradiation and 1 hour after
irradiation with solar light simulator conducted at 500 W/m2 in 25 µM (4g) or 50 µM (2d, 3b, EHMC) methanol
solutions. Figure S5: The chromatograms and mass spectra of methanol solutions of compounds 3b and 4g
pre-irradiation (A) and 1 hour after irradiation (B) with solar light simulator conducted at 500 W/m2. Table S1:
Molecules 2019, 24, 2321 25 of 29
Parameters of intermolecular interactions in the crystal structures of 3b and 4g. Table S2: UV absorption changes
after 1h irradiation at 500 W/m2 of methanol solution of tested compounds and reference UV-filters. Table S3:
Mutagenic activity of compounds 4g and 3b tested with the Ames assay.
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